Hung Hao-Chien, Hsu Po-Jung, Chang Ting-Chang, Chou Hung-Hsueh, Huang Kuan-Gen, Lai Chyong-Huey, Lee Chao-Wei, Yu Ming-Chin, You Jeng-Fu, Hsu Yu-Jen, Hsu Jun-Te, Wu Ting-Jung
Department of General Surgery, Chang-Gung Memorial Hospital at Linkou, College of Medicine, Chang-Gung University, Taoyuan 333, Taiwan.
Department of Obstetrics and Gynecology, Chang-Gung Memorial Hospital at Linkou, College of Medicine, Chang-Gung University, Taoyuan 333, Taiwan.
J Pers Med. 2021 Dec 6;11(12):1313. doi: 10.3390/jpm11121313.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a therapeutic approach used to achieve curative treatment in intra-abdominal malignancy with peritoneal carcinomatosis (PC). However, it is a complicated procedure with high post-operative complication rates. Thus, we analyzed our preliminary data to establish whether multidisciplinary teamwork (MDT) implementation is beneficial for CRS-HIPEC outcomes.
A series of 132 consecutive patients with synchronous or recurrent PC secondary to gastrointestinal or gynecologic cancer who received CRS-HIPEC operation between May 2015 and September 2017 were included. Ninety-nine patients were categorized into the MDT group, with the 33 other patients into the non-MDT group.
The mean PCI score was 16.3 ± 8.8. Patients in the MDT group more often presented a higher PCI score ( value = 0.038). Regarding CRS completeness (CCR 0-1), it was distributed 81.8% and 57.6% in the MDT and the non-MDT group, respectively ( value = 0.005). Although post-operative complications were common ( = 62, 47.0%), post-operative complication rates did not differ between the two groups. The cumulative OS survival rate at the first year was 75.5%. Older age ( = 0.030, HR = 4.58, 95% CI = 1.16-18.10), ECOG 2 ( = 0.030, HR = 6.41, 95% CI = 1.20-34.14), and incomplete cytoreduction ( = 0.048, HR = 2.79, 95% CI = 1.04-8.27) were independent prognostic factors for survival.
Our experience suggests that the CRS-HIPEC performed under MDT cooperation may result in higher complete cytoreduction rates without increasing post-operative complications and hospital mortalities.
细胞减灭术联合腹腔热灌注化疗(CRS-HIPEC)是一种用于治疗伴有腹膜癌转移(PC)的腹腔恶性肿瘤以实现根治性治疗的方法。然而,这是一个复杂的手术,术后并发症发生率很高。因此,我们分析了我们的初步数据,以确定多学科团队合作(MDT)的实施是否有利于CRS-HIPEC的治疗结果。
纳入2015年5月至2017年9月期间连续接受CRS-HIPEC手术的132例因胃肠道或妇科癌症继发的同步或复发性PC患者。99例患者被归入MDT组,另外33例患者归入非MDT组。
平均PCI评分为16.3±8.8。MDT组患者的PCI评分更高(P值=0.038)。关于CRS的完整性(CCR 0-1),MDT组和非MDT组分别为81.8%和57.6%(P值=0.005)。虽然术后并发症很常见(n=62,47.0%),但两组之间的术后并发症发生率没有差异。第一年的累积总生存率为75.5%。年龄较大(P=0.030,HR=4.58,95%CI=1.16-18.10)、ECOG 2(P=0.030,HR=6.41,95%CI=1.20-34.14)和细胞减灭不完全(P=0.048,HR=2.79,95%CI=1.04-8.27)是生存的独立预后因素。
我们的经验表明,在MDT合作下进行的CRS-HIPEC可能会提高完全细胞减灭率,而不会增加术后并发症和医院死亡率。